Craft

Lophius Biosciences

Total Funding

$14.4 M

Lophius Biosciences Summary

Company Summary

Overview
Lophius Biosciences is a biotechnology company focusing on the development and marketing of innovative immune diagnostic systems to improve therapy control and personalized treatment of patients in the area of transplantation, infectious and autoimmune diseases.The company’s developments are based on its expertise in cell-mediated immunity as well as on its proprietary T-activation and Reverse T Cell Technology platforms. Whereas the T-activation technology platform allows an efficient stimulation of a broad spectrum of clinically-relevant immune effector cells to accurately measure the cell-mediated immunity, the Reverse T Cell Technology platform can distinguish between active and memory T cells to develop innovative diagnostics. With its T-Track CMV leading product, based on T-activation technology, Lophius offers a sensitive, reliable and standardized CE-marked in vitro diagnostic solution to measure the functionality of CMV-specific cell-mediated immunity. T-Track CMV assists clinicians in the risk stratification of CMV disease in immunocompromised patients, toward an improved and individualized patient management.
Type
Private
Status
Active
Founded
2002
HQ
Regensburg, DE | view all locations
Website
http://www.lophius.com/
Cybersecurity rating
Sectors

Key People

  • Bernd Merkl

    Bernd Merkl, Chief Executive Officer (CEO) / Managing Director

    • Ludwig Deml

      Ludwig Deml, Chief Scientific Officer (CSO)

      • Ralf Wagner

        Ralf Wagner, Chairman of the Board (COB)

        LocationsView all

        1 location detected

        • Regensburg, Bayern HQ

          Germany

          13 Am Biopark

        Footer menu